Inhibitors of prenyl transferases

Said Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

Because farnesylation of Ras is required for its cancer-causing activity, several classes of farnesyl transferase inhibitors have recently been developed as potential anticancer drugs. During the last 12 months, important advances have been made in this field. In this review, we focus on three topics: targets of farnesyl transferase inhibitors other than Ras, alternative prenylation of K-Ras by the closely related prenyl transferase, geranyl geranyl transferase I, and the effects of geranyl geranyl transferase I inhibitors on cell cycle, apoptosis, and human tumor growth.

Original languageEnglish (US)
Pages (from-to)557-561
Number of pages5
JournalCurrent Opinion in Oncology
Volume9
Issue number6
StatePublished - 1997

Fingerprint

Transferases
Prenylation
Neoplasms
Cell Cycle
prenyl
Apoptosis
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Inhibitors of prenyl transferases. / Sebti, Said; Hamilton, Andrew.

In: Current Opinion in Oncology, Vol. 9, No. 6, 1997, p. 557-561.

Research output: Contribution to journalArticle

Sebti, Said ; Hamilton, Andrew. / Inhibitors of prenyl transferases. In: Current Opinion in Oncology. 1997 ; Vol. 9, No. 6. pp. 557-561.
@article{09f21ee4b18946b48fb79d3f49265f3e,
title = "Inhibitors of prenyl transferases",
abstract = "Because farnesylation of Ras is required for its cancer-causing activity, several classes of farnesyl transferase inhibitors have recently been developed as potential anticancer drugs. During the last 12 months, important advances have been made in this field. In this review, we focus on three topics: targets of farnesyl transferase inhibitors other than Ras, alternative prenylation of K-Ras by the closely related prenyl transferase, geranyl geranyl transferase I, and the effects of geranyl geranyl transferase I inhibitors on cell cycle, apoptosis, and human tumor growth.",
author = "Said Sebti and Andrew Hamilton",
year = "1997",
language = "English (US)",
volume = "9",
pages = "557--561",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Inhibitors of prenyl transferases

AU - Sebti, Said

AU - Hamilton, Andrew

PY - 1997

Y1 - 1997

N2 - Because farnesylation of Ras is required for its cancer-causing activity, several classes of farnesyl transferase inhibitors have recently been developed as potential anticancer drugs. During the last 12 months, important advances have been made in this field. In this review, we focus on three topics: targets of farnesyl transferase inhibitors other than Ras, alternative prenylation of K-Ras by the closely related prenyl transferase, geranyl geranyl transferase I, and the effects of geranyl geranyl transferase I inhibitors on cell cycle, apoptosis, and human tumor growth.

AB - Because farnesylation of Ras is required for its cancer-causing activity, several classes of farnesyl transferase inhibitors have recently been developed as potential anticancer drugs. During the last 12 months, important advances have been made in this field. In this review, we focus on three topics: targets of farnesyl transferase inhibitors other than Ras, alternative prenylation of K-Ras by the closely related prenyl transferase, geranyl geranyl transferase I, and the effects of geranyl geranyl transferase I inhibitors on cell cycle, apoptosis, and human tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=0030829794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030829794&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 557

EP - 561

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -